Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5
- PMID: 23269796
- PMCID: PMC3571396
- DOI: 10.1128/JVI.02964-12
Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5
Abstract
Infection by HIV-1 most often results from the successful transmission and propagation of a single virus variant, termed the transmitted/founder (T/F) virus. Here, we compared the attachment and entry properties of envelope (Env) glycoproteins from T/F and chronic control (CC) viruses. Using a panel of 40 T/F and 47 CC Envs, all derived by single genome amplification, we found that 52% of clade C and B CC Envs exhibited partial resistance to the CCR5 antagonist maraviroc (MVC) on cells expressing high levels of CCR5, while only 15% of T/F Envs exhibited this same property. Moreover, subtle differences in the magnitude with which MVC inhibited infection on cells expressing low levels of CCR5, including primary CD4(+) T cells, were highly predictive of MVC resistance when CCR5 expression levels were high. These results are consistent with previous observations showing a greater sensitivity of T/F Envs to MVC inhibition on cells expressing very high levels of CCR5 and indicate that CC Envs are often capable of recognizing MVC-bound CCR5, albeit inefficiently on cells expressing physiologic levels of CCR5. When CCR5 expression levels are high, this phenotype becomes readily detectable. The utilization of drug-bound CCR5 conformations by many CC Envs was seen with other CCR5 antagonists, with replication-competent viruses, and did not obviously correlate with other phenotypic traits. The striking ability of clade C and B CC Envs to use MVC-bound CCR5 relative to T/F Envs argues that the more promiscuous use of CCR5 by these Env proteins is selected against at the level of virus transmission and is selected for during chronic infection.
Figures
Similar articles
-
C-C chemokine receptor type 5 (CCR5) utilization of transmitted and early founder human immunodeficiency virus type 1 envelopes and sensitivity to small-molecule CCR5 inhibitors.J Gen Virol. 2010 Dec;91(Pt 12):2965-73. doi: 10.1099/vir.0.025270-0. Epub 2010 Sep 1. J Gen Virol. 2010. PMID: 20810746 Free PMC article.
-
Frequency and Env determinants of HIV-1 subtype C strains from antiretroviral therapy-naive subjects that display incomplete inhibition by maraviroc.Retrovirology. 2016 Nov 3;13(1):74. doi: 10.1186/s12977-016-0309-2. Retrovirology. 2016. PMID: 27809912 Free PMC article.
-
A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations.Retrovirology. 2013 Apr 20;10:43. doi: 10.1186/1742-4690-10-43. Retrovirology. 2013. PMID: 23602046 Free PMC article.
-
[Pharmacokinetics, interactions and mechanism of action of maraviroc].Enferm Infecc Microbiol Clin. 2008 Oct;26 Suppl 11:12-6. doi: 10.1016/s0213-005x(08)76558-3. Enferm Infecc Microbiol Clin. 2008. PMID: 19133216 Review. Spanish.
-
[Viral entry as therapeutic target. Current situation of entry inhibitors].Enferm Infecc Microbiol Clin. 2008 Oct;26 Suppl 11:5-11. doi: 10.1016/s0213-005x(08)76557-1. Enferm Infecc Microbiol Clin. 2008. PMID: 19133215 Review. Spanish.
Cited by
-
Activity and structural analysis of GRL-117C: a novel small molecule CCR5 inhibitor active against R5-tropic HIV-1s.Sci Rep. 2019 Mar 18;9(1):4828. doi: 10.1038/s41598-019-41080-w. Sci Rep. 2019. PMID: 30886166 Free PMC article.
-
Defining differential genetic signatures in CXCR4- and the CCR5-utilizing HIV-1 co-linear sequences.PLoS One. 2014 Sep 29;9(9):e107389. doi: 10.1371/journal.pone.0107389. eCollection 2014. PLoS One. 2014. PMID: 25265194 Free PMC article.
-
Resistance to type 1 interferons is a major determinant of HIV-1 transmission fitness.Proc Natl Acad Sci U S A. 2017 Jan 24;114(4):E590-E599. doi: 10.1073/pnas.1620144114. Epub 2017 Jan 9. Proc Natl Acad Sci U S A. 2017. PMID: 28069935 Free PMC article.
-
Characterization of HIV-1 envelopes in acutely and chronically infected injection drug users.Retrovirology. 2014 Nov 28;11:106. doi: 10.1186/s12977-014-0106-8. Retrovirology. 2014. PMID: 25430652 Free PMC article.
-
Distinct HIV-1 entry phenotypes are associated with transmission, subtype specificity, and resistance to broadly neutralizing antibodies.Retrovirology. 2014 Jun 23;11:48. doi: 10.1186/1742-4690-11-48. Retrovirology. 2014. PMID: 24957778 Free PMC article.
References
-
- Derdeyn CA, Decker JM, Bibollet-Ruche F, Mokili JL, Muldoon M, Denham SA, Heil ML, Kasolo F, Musonda R, Hahn BH, Shaw GM, Korber BT, Allen S, Hunter E. 2004. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303:2019–2022 - PubMed
-
- Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, Sun C, Grayson T, Wang S, Li H, Wei X, Jiang C, Kirchherr JL, Gao F, Anderson JA, Ping L-H, Swanstrom R, Tomaras GD, Blattner WA, Goepfert PA, Kilby JM, Saag MS, Delwart EL, Busch MP, Cohen MS, Montefiori DC, Haynes BF, Gaschen B, Athreya GS, Lee HY, Wood N, Seoighe C, Perelson AS, Bhattacharya T, Korber BT, Hahn BH, Shaw GM. 2008. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. U. S. A. 105:7552–7557 - PMC - PubMed
-
- Pang S, Shlesinger Y, Daar ES, Moudgil T, Ho DD, Chen IS. 1992. Rapid generation of sequence variation during primary HIV-1 infection. AIDS 6:453–460 - PubMed
-
- Wolfs TF, Zwart G, Bakker M, Goudsmit J. 1992. HIV-1 genomic RNA diversification following sexual and parenteral virus transmission. Virology 189:103–110 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 AI094604/AI/NIAID NIH HHS/United States
- UM1 AI100645/AI/NIAID NIH HHS/United States
- T32 AI007632/AI/NIAID NIH HHS/United States
- R01 AI045378/AI/NIAID NIH HHS/United States
- R01 AI41420/AI/NIAID NIH HHS/United States
- P01 AI088564/AI/NIAID NIH HHS/United States
- U19 AI067854/AI/NIAID NIH HHS/United States
- R37 AI045378/AI/NIAID NIH HHS/United States
- P30 CA016520/CA/NCI NIH HHS/United States
- T32 AI 07632/AI/NIAID NIH HHS/United States
- R01 AI041420/AI/NIAID NIH HHS/United States
- R01 AI45378/AI/NIAID NIH HHS/United States
- R01 AI04088/AI/NIAID NIH HHS/United States
- UM1-AI100645-01/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous